TTS Pharma’s CBD Animal Studies Show Anti-Inflammatory Potential
Executive Summary
Can cannabinoids provide therapeutic benefits to consumers? A new animal study by the UK's TTS Pharma suggests anti-inflammatory properties for CBD, according to the company's director of Medical Affairs, Rob Walton.
You may also be interested in...
Hiding In Plain Sight: Can TTS Pharma’s ‘Assured Advice’ Unlock UK’s CBD Mass Market?
UK CBD supplier TTS Pharma believes its strategy of establishing partnerhips with local food law enforcement agencies as part of the "assured advice" scheme will unlock the country's cautious mass market. However, without proactive enforcement, the company worries that the UK food authority's legislative efforts to remove sub-standard CBD products from the market, as well as TTS' own efforts to become compliant, will be in vain.
TTS Pharma Wants To Bring First Legal CBD Oil To The UK
TTS Pharma CEO Mark Tucker discusses his ambition to bring a legal CBD oil to the UK market, following the recent submission of a European Union novel food application.
Patience Wins The Race: TTS Pharma's CEO On Bringing The First Legal CBD Oil To The UK Market
TTS Pharma wants to be the first to launch a legal CBD oil onto the UK wellness market. TTS CEO Mark Tucker explains how his firm's CBD is produced according to strict standards and can provide a model for future regulation.